This piece is about Agilent, a lab instrument company that makes most of its money from consumables and services, not equipment sales (only 1/3 of revenue). The guest sees it as an undervalued 'boring' business with a 34% service margin and a 2/3 share in gas chromatography, backed by 4,000 technicians. Key holdings: Agilent (service attach rate rising from 30% to 50%), Waters (higher attach rate at 50%), and Thermo Fisher (huge product range, but chromatography is just one part).
Agilent is a laboratory instruments and equipment company with a market capitalization of approximately $30 billion, primarily serving the life sciences, diagnostics, and applied chemical markets. The company originated from Hewlett-Packard and was spun off 25 years ago, giving it deep industry root
Mark de Vos (fund manager at Troy Asset Management) is this episode's guest, analyzing Agilent—a life science tools company with a market cap of roughly $30 billion, tracing its roots to HP and specializing in laboratory instruments and consumables. The most significant judgment of the entire episode: Agilent does not make money from one-time equipment sales, but rather operates on a "razor and blade" model—instrument sales account for only 1/3 of revenue, while consumables and services account for 2/3, and the service business has a profit margin of 34%. However, the market underestimates the compounding growth potential of this "boring business."
Mark de Vos argues that Agilent's core business logic is not selling equipment, but rather locking in customers through equipment and then continuously selling consumables and services, forming highly sticky revenue.
| Indicator | Value |
|---|---|
| Instrument sales share | Approximately 1/3 |
| Consumables & services share | Approximately 2/3 |
| Typical chromatograph selling price | Approximately $100,000 |
| Useful life | 6–10 years |
| Total consumables & services spend over lifetime | Approximately $100,000 |
| Column replacement frequency | Every 2,000 samples or monthly |
| Current service contract attach rate | Low 30% |
| Peer Waters attach rate | Approximately 50% |
| Expected annual attach rate increase | Approximately 1 percentage point |
Mark de Vos argues that Agilent holds a dominant share in gas chromatography, and its service network is a more durable moat than technological innovation.
| Competitive Dimension | Agilent | Waters | Thermo Fisher |
|---|---|---|---|
| Total Revenue | ~$6.5B | ~$3B | ~$43B |
| Gas Chromatography Share | ~2/3 | Very low | Present but not dominant |
| Liquid Chromatography Share | ~1/3 | ~1/3 | Has share |
| Spectroscopy Share | 40-50% | Relatively low | Has share |
| Service Technician Scale | 4,000 | Smaller | Very large but fragmented |
| Customer Concentration | Diversified (pharma, food, environmental, semiconductor) | ~60% pharma | Extremely broad |
Mark de Vos argues that Agilent's self-developed 'Nucleic Acid Solutions Division' (NASD) and the emerging PFAS (forever chemicals) testing market are potential growth catalysts beyond the traditional business framework, but attention must be paid to their commercialization uncertainties.
| Emerging Business | Current Revenue Scale | Growth Trend | Key Risks |
|---|---|---|---|
| NASD (oligos) | Approximately $470 million (about 7% of total revenue) | High growth, but depends on RNA drug commercialization | Low single-client dependency risk, but industry financing environment volatile |
| PFAS Testing | Market of approximately $400 million | 20% annual growth | Regulatory pace uncertain, but Agilent has already taken the lead |
Mark de Vos believes that Agilent's current valuation – a P/E of roughly 22x and a free cash flow yield above 4% – is reasonable for a business with high single-digit growth and high cash conversion, but the market still underestimates the compounding power of its "boring business."
| Valuation Metric | Current Level | Historical Range |
|---|---|---|
| Free Cash Flow | ~$1.4 billion | Annual conversion rate ~90% of adjusted net income |
| Free Cash Flow Yield | Over 4% | Near 10-year high |
| P/E (Price-to-Earnings) | ~22x | Comparable to the 10-year historical median |
| Organic Revenue Growth (CAGR) | ~5% (2015-2024) | - |
| EPS Growth (CAGR) | ~13% (2015-2024) | Driven by margin expansion |
| Instrument | Guest Attitude | Key Data |
|---|---|---|
| Agilent | Bullish | Market cap ~$30B; revenue ~$6.5B; free cash flow ~$1.4B; service margin 34%; gas chromatography market share ~2/3 |
| Waters | Neutral (competitive comparison) | Revenue ~$3B; liquid chromatography share ~1/3; service contract stickiness ~50% (higher than Agilent) |
| Thermo Fisher Scientific | Neutral (competitive comparison) | Revenue ~$43B; extremely broad product line, chromatography is only one segment; service network fragmented |
| BioVectra | Bullish (acquisition) | ~$1B acquisition; complements NASD business, combined revenue of ~$470 million post-acquisition |
| Keysight Technologies | Background mention | Spun off from Agilent in 2014, currently listed independently; Agilent divested ~40% of its sales revenue at the time |
| Broadcom (via Avago) | Background mention | Agilent's former semiconductor components business was acquired by KKR/Silver Lake to become Avago, later merged into Broadcom |
1. Mark de Vos: "The Underestimated 'Boring' Business" — Agilent's services business has a 33% margin, grows high single digits, and its "stickiness" still has a long way to go from the low 30% to 50%, but the market overlooks its quality due to the "repairing lab instruments" label.
2. Mark de Vos: "Tool Suppliers Outperform End Users" — Life science tool companies have long outperformed pharmaceutical companies. Agilent is a classic "selling shovels" example and benefits from customer stickiness driven by regulatory lock-in.
3. Mark de Vos: "Service Is the True Moat, Not Technology" — 4,000 technicians, 75% holding chemistry/biochemistry degrees, and 2,500 on-site service visits per day form a barrier more difficult to replicate than technology patents.
4. Mark de Vos: "The Cost for Customers to Switch Suppliers Is Nearly Infinite" — Once FDA approval documents specify Agilent's instruments and consumables, switching means re-approval, enormous costs, and uncontrollable risks. This is the fundamental source of "stickiness."
5. Mark de Vos: "Gas Chromatography Is Agilent's 'Crown Jewel'" — 2/3 global market share, covering non-cyclical application markets such as battery testing, environmental testing, petrochemical refining, and with a customer base that largely does not overlap with liquid chromatography, forming a natural hedge.
6. Mark de Vos: "The NASD Business Is a 'Rebirth of an Old Business'" — Starting from a small, inconspicuous merger in 2006, after 20 years of R&D, it has become a core supplier for RNA drug production, with unmatched capacity. Falsification Condition: If the commercialization progress of RNA drugs falls short of expectations, or if alternative technologies emerge, the investment may not be recovered.
7. Mark de Vos: "PFAS Testing Is an 'Unexpected Catalyst'" — A $400 million market that "suddenly emerged" from regulation, growing 20% annually, with Agilent as the clear leader. This provides investors with a "free option."
8. Mark de Vos: "22x PE Is Reasonable, But Don't Expect Valuation Expansion" — For a business with high single-digit growth and 90% cash conversion, the current valuation already reflects its quality. Excess returns will come from earnings growth, not multiple expansion.